Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9997222 | 0.87 | MCL1 (0.62) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL3504223 | 0.87 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ATSHRPTPN5 | |
| SCHEMBL9997330 | 0.85 | MCL1 (0.70) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL11222668 | 0.85 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL7828166 | 0.85 | MCL1 (0.78) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL17340522 | 0.85 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ATSHRPTPN5 | |
| SCHEMBL9997248 | 0.85 | MCL1 (0.62) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL9997019 | 0.85 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL9997287 | 0.85 | HSD17B10 (0.67) | ALDH1A1MEN1KMT2ATSHRMCL1 | |
| SCHEMBL97271 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ATSHRPTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | claimed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | claimed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | ALDH1A1 1943/4885MEN1 3253/4885KMT2A 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.